As incretin therapies expand in paediatric obesity and diabetes treatment, community pharmacists are navigating evolving approvals, clinical evidence, and safety considerations to best support young patients’ health outcomes.
Pharmacists are being asked to navigate a fast-moving corner of paediatric medicine where product names, approved ages and diagnoses do not always align neatly. In the United States, injectable semaglutide sold as Wegovy is approved for obesity from age 12, while liraglutide marketed as Saxenda is cleared for adolescents aged 12 and older who weigh more than 60 kilograms. By contrast, diabetes approvals differ: Victoza and Mounjaro have paediatric type 2 diabetes indications beginning at age 10, whereas semaglutide products do not yet have an approved paediatric diabetes label. That makes the pharmacist’s verification role especially important before a prescription is dispensed.
The clinical evidence for incretin-based therapies in young people is encouraging, particularly for weight reduction. In the STEP Teens trial, weekly semaglutide cut mean body mass index by 16.1% over 68 weeks in adolescents aged 12 to 17, compared with a 0.6% increase in the placebo group. A broader meta-analysis of 15 randomised paediatric trials, involving 1,286 participants, found that these medicines produced a statistically significant average weight loss of 2.89 kilograms versus control treatment. The same analysis also showed improvements in glycated haemoglobin and fasting plasma glucose, suggesting benefits for both weight and metabolic control.
Safety remains a central part of the discussion. Gastrointestinal side effects, including nausea and vomiting, are the most common problems, and gallstone-related events can occur, but severe hypoglycaemia is uncommon because these drugs stimulate insulin release in a glucose-dependent manner. Early studies are also exploring whether semaglutide may have a role in younger children aged 6 to 11, though researchers still do not know whether treating obesity early can prevent later cardiovascular disease or kidney failure. For now, the evidence supports cautious use with close monitoring rather than assumptions about long-term protection.
The practical challenge is turning that evidence into routine care. Surveys cited in the related research show that many community pharmacists recognise obesity as a major health problem, but far fewer have formal training in weight management, even though they see patients more often than many other clinicians. Reviews of successful pharmacy-based weight programmes suggest that multidisciplinary working is usually a key feature, which helps explain why community pharmacies can be effective access points, especially in underserved areas. Counselling needs to cover gradual dose escalation, managing stomach-related side effects, watching for possible nutritional deficiencies, and offering non-judgemental support around weight stigma and mental health. Pharmacists also need to flag reproductive counselling issues, including the possibility that tirzepatide may affect oral contraceptive use, and to reinforce the importance of long-term behaviour support for children and families.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
